VATS Lobectomy for Clinical Stage IB or II Lung Cancer

Inclusion Criteria:

1. Histologic or cytologic diagnosis of non-small cell lung cancer.
2. Clinical stage IB or II, according to the American Joint Committee on Cancer (AJCC).
3. Tumor ≤ 6 cm in size amenable to surgical resection.
4. Including clinical IB or II NSCLC after neoadjuvant therapy
5. Performance status of 0-1 on ECOG scale.
6. At least 18 years old.
7. Patient compliance that allows adequate follow-up.
8. Medical fitness of patients adequate for radical NSCLC surgery.
9. Adequate organ function including the following:Adequate hematologic function: WBC count ³ 4,000/uL, absolute neutrophil count (ANC) ³ 1,500/uL, platelet count ³ 100,000/uL, and hemoglobin ³ 10 gm/dL.Adequate hepatic function: bilirubin £ 1.5 x UNL, ALT or AST £ 2.5 x UNL.Adequate renal function: creatinine £ 1.5mg/dL.
10. Signed informed consent from patient or legal representative.
11. Patients with reproductive potential must use an approved contraceptive method during and for 3 months after the study. Females with childbearing potential must have a negative urine hCG test within 7 days prior to study enrollment.

Exclusion Criteria:

1. Metastatic disease in workup
2. Any T3, T4 lesion or N2, N3 lesion
3. Concurrent administration of other tumor therapy, including radiotherapy, immunotherapy except chemotherapy.
4. Active uncontrolled infection.
5. Serious concomitant disorders that would compromise the safety of patient or compromise the patient's ability to tolerate therapy.
6. Significant neurological or mental disorder.
7. Previous history of malignancy in any organ
8. Pregnant or nursing.